Back to Search Start Over

Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer...

Authors :
Azad, Arun
Gurney, Howard
Underhill, Craig
Horvath, Lisa
Voskoboynik, Mark
Li, Xinghai
King, Ivan
Shao, Lisa
Dai, Yiyun
Perabo, Frank
Source :
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p124-124, 235p
Publication Year :
2024

Details

Language :
English
ISSN :
0732183X
Volume :
42
Database :
Supplemental Index
Journal :
Journal of Clinical Oncology
Publication Type :
Academic Journal
Accession number :
175073804
Full Text :
https://doi.org/10.1200/JCO.2024.42.4_suppl.124